You are here: Welcome » COVID-19 Vaccines » COVID-19 Vaccine Efficacy

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
covid-19_vaccines:efficacy [2022/09/23 18:44]
mathew [Retrospective Analyses] 		covid-19_vaccines:efficacy [2022/10/21 18:11] (current)
xinke [Waning Efficacy]
Line 26: Line 26:
   * Nov 18, 2021 - Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status((November 18, 2021 | Celine Boschi et al | Emerging Microbes and Infections | Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status | [[https://cogentoa.tandfonline.com/doi/full/10.1080/22221751.2021.2008776|doi.org/10.1080/22221751.2021.2008776]]))   * Nov 18, 2021 - Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status((November 18, 2021 | Celine Boschi et al | Emerging Microbes and Infections | Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status | [[https://cogentoa.tandfonline.com/doi/full/10.1080/22221751.2021.2008776|doi.org/10.1080/22221751.2021.2008776]]))
   * June 23, 2022 - Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign((June 23, 2022 | Theodore Lytras et al | J Med Virol | Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign | [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349766/|doi: 10.1002/jmv.27934]]))   * June 23, 2022 - Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign((June 23, 2022 | Theodore Lytras et al | J Med Virol | Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign | [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349766/|doi: 10.1002/jmv.27934]]))
 +    * The lead author and a co-authored also authored a paper in support of lockdowns. That co-author is a spokesman with a spokesman for the [[Hellenic Ministry of Health]].((February, 2021 | Theodore Lytras and Sotirios Tsiodra | Scand J Public Health | Lockdowns and the COVID-19 pandemic: What is the endgame? | [[https://pubmed.ncbi.nlm.nih.gov/32981448/|DOI: 10.1177/1403494820961293]]))
 +    * The waning of VE from 90% to 80% is substantially less than from other reported retrospective results.
 +    * Says the olderly are more than 1000x as at risk as the young without even a word suggesting that absolute benefits may not justify the risks for the young.
 +
  
 ==== Surveillance Data ==== ==== Surveillance Data ====
Line 46: Line 50:
   * Deaths have increased 46.3% worldwide.   * Deaths have increased 46.3% worldwide.
  
- * [[:Mathew Crawford]] wrote at [[:Rounding the Earth]] about how there is no distinction in any [[:COVID-19 vaccine trials]] data or subsequent retrospective analyses that is inconsistent with the [[:hypothesis]] that the vaccines are ineffective. ([[https://roundingtheearth.substack.com/p/systemic-vaccine-efficacy-part-4|Systemic Vaccine Efficacy, Part 4]])+ * [[:Mathew Crawford]] wrote at [[:Rounding the Earth]] about how there is no distinction in any [[COVID-19 vaccines:COVID-19 vaccine trials]] data or subsequent retrospective analyses that is inconsistent with the [[:hypothesis]] that the vaccines are ineffective. ([[https://roundingtheearth.substack.com/p/systemic-vaccine-efficacy-part-4|Systemic Vaccine Efficacy, Part 4]])
  
 === Selective Reporting === === Selective Reporting ===
Line 73: Line 77:
  
 === Waning Booster Efficacy === === Waning Booster Efficacy ===
-Medpage Today reported that COVID vaccine booster efficacy may want quickly.((December 28, 2021 | MedPage Today | [[https://www.medpagetoday.com/special-reports/exclusives/96412|COVID Vaccine Booster Efficacy Against Infection May Fade Quickly]]))+Medpage Today reported that COVID vaccine booster efficacy may wane quickly.((December 28, 2021 | MedPage Today | [[https://www.medpagetoday.com/special-reports/exclusives/96412|COVID Vaccine Booster Efficacy Against Infection May Fade Quickly]]))
  
 ==== Efficacy by Variant ==== ==== Efficacy by Variant ====
Line 83: Line 87:
 === Efficacy vs. Delta === === Efficacy vs. Delta ===
   * Aug 12, 2021 - Bernal et al: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant ((August 12, 2021 | Bernal et al | [[:New England Journal of Medicine]] | [[https://www.nejm.org/doi/full/10.1056/nejmoa2108891|DOI: 10.1056/NEJMoa2108891]]))   * Aug 12, 2021 - Bernal et al: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant ((August 12, 2021 | Bernal et al | [[:New England Journal of Medicine]] | [[https://www.nejm.org/doi/full/10.1056/nejmoa2108891|DOI: 10.1056/NEJMoa2108891]]))
 +  * June 23, 2022 - Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign((June 23, 2022 | Theodore Lytras et al | J Med Virol | Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign | [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349766/|doi: 10.1002/jmv.27934]]))
 +    * This study from Greece concludes 90% VE which waves to 80% over six months, consistent over age bands.
  
 === Efficacy vs. Omicron === === Efficacy vs. Omicron ===
Back to top